Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Forecasted Market Size Estimates For The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Between 2025 And 2029?
The market size for chemotherapy-induced nausea and vomiting (cinv) has experienced robust growth in recent years. It is projected to expand from $2.92 billion in 2024 to $3.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. The expansion observed in the historical period can be attributed to an increase in chemotherapy use, the advent of improved antiemetic agents, the establishment of clinical guidelines, and strengthened patient advocacy.
The market size for chemotherapy-induced nausea and vomiting (CINV) is anticipated to experience robust expansion over the coming years. It is projected to reach $4.19 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.5%. Factors contributing to this growth during the projected period include personalized medicine, continuous advancements in antiemetic agents, the rise of telehealth and remote monitoring, and various health equity initiatives. Key trends foreseen in this forecast period encompass the adoption of combination antiemetic therapies, a focus on supportive care services, the integration of digital health tools, and enhanced survivorship care.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Which Major Market Drivers Are Shaping The Future Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The rising incidence of cancer is projected to fuel the expansion of the chemotherapy-induced nausea and vomiting (CINV) market in the coming years. Cancer is characterized by the uncontrolled proliferation and dissemination of certain cells throughout the body. The persistent increase in cancer diagnoses provides a stronger impetus for creating more potent and focused anti-emetic therapies to mitigate CINV, a troubling consequence of chemotherapy. This intensified emphasis on managing CINV has resulted in progress in deciphering its fundamental mechanisms and in pioneering new treatments. For example, the American Cancer Society (ACS), a US-based volunteer health organization dedicated to eradicating cancer, reported in January 2023 that the United States is expected to see 1.9 million new cancer cases (roughly 5,370 cases daily) and 609,820 cancer deaths (approximately 1,670 deaths per day) in 2023. Consequently, the expanding occurrence of cancer will propel the chemotherapy-induced nausea and vomiting (CINV) market.
What Are The Major Segment Types Covered In The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
The chemotherapy-induced nausea and vomiting (cinv)market covered in this report is segmented –
1) By Form: Injectables; Oral; Transdermal Patches
2) By Drug Class: 5-HT3 Receptor Antagonists; Neurokinin-1 Receptor Antagonists; Corticosteroids; Cannabinoids; Other Drug Class
3) By Emetogenic Risk: Highly Emetogenic Chemotherapy (HEC); Moderately Emetogenic Chemotherapy (MEC); Low Emetogenic Chemotherapy (LEC)
4) By Distribution Channel: CINV Hospitals; Cancer Research Institute; Retail Pharmacies; Online Pharmacies; Drug Stores
5) By Application: Gynecology; Urology; Gastrointestinal Surgery; Other Applications
Subsegments:
1) By Injectables: Intravenous (IV) Solutions; Intramuscular (IM) Injections
2) By Oral: Tablets; Capsules; Liquid Formulations
3) By Transdermal Patches: Fentanyl Patches; Scopolamine Patches
Which Trends Are Impacting The Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Leading companies in the chemotherapy-induced nausea and vomiting (CINV) market are pursuing new product innovations, such as fixed intravenous antiemetics, to gain a competitive advantage. A fixed intravenous antiemetic is defined as a specific dose of medication delivered via IV to prevent or treat nausea and vomiting, frequently employed in chemotherapy or post-surgical environments. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based producer of pharmaceuticals, generics, and over-the-counter products, launched AKYNZEO I.V. in India. This product represents the inaugural fixed intravenous antiemetic combination created to avert chemotherapy-induced nausea and vomiting (CINV). It combines netupitant and palonosetron, effectively targeting both the acute and delayed stages of nausea and vomiting. The solution offers the benefit of single-dose administration, yielding improved complete response rates and a better quality of life for cancer patients. Furthermore, clinical studies have demonstrated its specific utility for patients receiving highly emetogenic chemotherapy.
Which Global Market Leaders Are Shaping The Future Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Sector?
Major companies operating in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Download The Full Report For Exclusive Market Findings:
What Are The Regional Market Dynamics Impacting The Chemotherapy-Induced Nausea and Vomiting (CINV) Industry?
North America was the largest region in the chemotherapy-induced nausea and vomiting (CINV) market in 2024. The regions covered in chemotherapy-induced nausea and vomiting (CINV) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Chemotherapy-Induced Nausea and Vomiting (CINV) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13031&type=smp
Browse Through More Reports Similar to the Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market 2025, By The Business Research Company
Viral Vectors And Plasmid Dna Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025
Chemotherapy Induced Anemia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model